While asking patients about their symptoms during chemotherapy is not a new concept for oncology care, measuring outcomes related to symptom control is new.
MN Community Measurement is excited to announce the development of new patient-reported outcome measures for the symptom control of nausea, pain and constipation during chemotherapy. The Symptom Control During Chemotherapy (SCDC) measures were successfully tested and approved for widespread implementation in oncology practices across Minnesota and surrounding communities. Implementation of the measures will include 2019 dates of service with data reported in 2020.
Collecting and submitting data for these measures will:
- Support ongoing patient-centered care;
- Provide data to help inform understanding of treatment tolerance enabling the continuation of therapy; and
- Provide outcome rates that will support national endorsement of these measures.
To participate, the most important first step for oncology practices is to begin administration of the patient assessment tool prior to January 1, 2019. The tool needs to be integrated into clinical workflows to capture information reported by patients during Day 5 to 15 of each chemotherapy cycle; measurement occurs for cycles 1, 2 and 3. MNCM has obtained permission from the National Cancer Institute for the use of six individual questions from the Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE) tool.
Educational Information and Resources: